These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30477842)

  • 1. Vitamin A supplementation decreases disease activity index in patients with ulcerative colitis: A randomized controlled clinical trial.
    Masnadi Shirazi K; Nikniaz Z; Masnadi Shirazi A; Rohani M
    Complement Ther Med; 2018 Dec; 41():215-219. PubMed ID: 30477842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
    Naganuma M; Sugimoto S; Mitsuyama K; Kobayashi T; Yoshimura N; Ohi H; Tanaka S; Andoh A; Ohmiya N; Saigusa K; Yamamoto T; Morohoshi Y; Ichikawa H; Matsuoka K; Hisamatsu T; Watanabe K; Mizuno S; Suda W; Hattori M; Fukuda S; Hirayama A; Abe T; Watanabe M; Hibi T; Suzuki Y; Kanai T;
    Gastroenterology; 2018 Mar; 154(4):935-947. PubMed ID: 29174928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study.
    Barreiro-de Acosta M; Vallejo N; de la Iglesia D; Uribarri L; Bastón I; Ferreiro-Iglesias R; Lorenzo A; Domínguez-Muñoz JE
    J Crohns Colitis; 2016 Jan; 10(1):13-9. PubMed ID: 26351390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score.
    Jairath V; Jeyarajah J; Zou G; Parker CE; Olson A; Khanna R; D'Haens GR; Sandborn WJ; Feagan BG
    Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):63-70. PubMed ID: 30343116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of mucosal healing during induction therapy in patients with acute moderate-to-severe ulcerative colitis.
    Motobayashi M; Matsuoka K; Takenaka K; Fujii T; Nagahori M; Ohtsuka K; Iwamoto F; Tsuchiya K; Negi M; Eishi Y; Watanabe M
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1004-1010. PubMed ID: 30551266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Explore the influence of vitamin D supplementation on clinical efficacy and drug retention rate of vedolizumab in patients with ulcerative colitis].
    Xiao HY; Rao SY; Zhang DL; Ma GL; Xu Y; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(23):1759-1766. PubMed ID: 37305935
    [No Abstract]   [Full Text] [Related]  

  • 7. Vitamin D Decreases Beck Depression Inventory Score in Patients with Mild to Moderate Ulcerative Colitis: A Double-Blind Randomized Placebo-Controlled Trial.
    Sharifi A; Vahedi H; Nedjat S; Mohamadkhani A; Hosseinzadeh Attar MJ
    J Diet Suppl; 2019; 16(5):541-549. PubMed ID: 29958055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status.
    Karimi S; Tabataba-Vakili S; Yari Z; Alborzi F; Hedayati M; Ebrahimi-Daryani N; Hekmatdoost A
    Nutr J; 2019 Mar; 18(1):16. PubMed ID: 30871542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.
    Yoshimura N; Watanabe M; Motoya S; Tominaga K; Matsuoka K; Iwakiri R; Watanabe K; Hibi T;
    Gastroenterology; 2015 Dec; 149(7):1775-1783.e2. PubMed ID: 26327130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of clinical indexes in ulcerative colitis patients in regular follow-up visit: correlation with endoscopic 'mucosal healing' and implication for management. Preliminary results.
    Pagnini C; Menasci F; Festa S; Rizzatti G; Corleto VD; Delle Fave MM; D'Ambra G; Di Giulio E; Delle Fave G
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3674-81. PubMed ID: 26502857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial.
    Ahamed Z R; Dutta U; Sharma V; Prasad KK; Popli P; Kalsi D; Vaishnavi C; Arora S; Kochhar R
    J Clin Gastroenterol; 2019; 53(10):e409-e415. PubMed ID: 31356558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis.
    Kerur B; Litman HJ; Stern JB; Weber S; Lightdale JR; Rufo PA; Bousvaros A
    World J Gastroenterol; 2017 May; 23(18):3322-3329. PubMed ID: 28566893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score.
    Ikeya K; Hanai H; Sugimoto K; Osawa S; Kawasaki S; Iida T; Maruyama Y; Watanabe F
    J Crohns Colitis; 2016 Mar; 10(3):286-95. PubMed ID: 26581895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
    Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
    Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
    Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis.
    Theede K; Holck S; Ibsen P; Ladelund S; Nordgaard-Lassen I; Nielsen AM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1929-36.e1. PubMed ID: 26051392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
    N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.